drugset / Trial / NCT00810030
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how safe, tolerable and effective the new standardised dosage regimen of FERINJECT® infusions is, compared with a well established intravenous iron treatment.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-12
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric carboxymaltose | Other / unclassified | 500 mg | Intravenous |
| Subject | Ferric carboxymaltose | Other / unclassified | 1000 mg | Intravenous |
| Subject | Ferric carboxymaltose | Other / unclassified | 1500 mg | Intravenous |
| Comparator | Iron sucrose | Unknown | 200 mg | Intravenous |